Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to improving patients' lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. Headquartered in Dublin, Ireland, with U.S. offices in Palo Alto, CA, and Philadelphia, PA, Jazz Pharmaceuticals employs over 875 people worldwide, fostering a highly collaborative and entrepreneurial culture.
Core Business: Jazz Pharmaceuticals focuses on three main therapeutic areas: sleep, hematology/oncology, and pain. The company's diverse product portfolio includes nine approved therapies across neuroscience and oncology indications. Notable products include Xyrem and Xywav for narcolepsy, Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Epidiolex for severe forms of epilepsy, acquired through the purchase of GW Pharmaceuticals in May 2021.
Recent Achievements: In 2023, Jazz Pharmaceuticals reported strong financial performance, achieving over $3.8 billion in total revenue. The company also completed enrollment for a Phase 3 trial of Zepzelca in first-line small cell lung cancer and advanced several late-stage pipeline projects. In May 2024, the U.S. FDA accepted the Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, with a Priority Review designation for treating biliary tract cancer.
Current Projects: Jazz Pharmaceuticals remains committed to expanding its product portfolio through R&D and strategic acquisitions. Ongoing projects include the development of zanidatamab for multiple HER2-expressing cancers, the Phase 3 trial for the combination of zanidatamab with standard chemotherapy for advanced gastric cancer, and the optimization of Epidiolex for broader epilepsy indications.
Financial Condition: As of December 31, 2023, Jazz Pharmaceuticals reported cash and cash equivalents of $1.6 billion. The company sustained a strong operational cash flow, generating $1.09 billion in 2023. Despite an outstanding long-term debt of $5.8 billion, Jazz's disciplined capital allocation supports continued investment in growth and innovation.
Partnerships: The company has key collaborations with various organizations, including BeiGene, Ltd. for the development of zanidatamab. Additionally, Jazz Pharmaceuticals has a strategic partnership with Life Science Cares to drive social impact through employee volunteerism in the U.S., reinforcing its commitment to community engagement.
Jazz Pharmaceuticals continues to innovate and advance its mission to transform lives through pioneering therapeutics in oncology and neuroscience, positioning itself as a leader in addressing complex and unmet medical needs.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2023 first quarter financial results on May 10, 2023, after U.S. market close. The management will host a live audio webcast at 4:30 p.m. ET to discuss the financial results and provide updates on the business. Interested parties can register for the call in advance via the company’s website. A replay of the webcast will also be available subsequently.
Jazz Pharmaceuticals is focused on developing innovative treatments for serious diseases, with a robust portfolio that includes marketed medicines and novel products across neuroscience and oncology. The company operates globally, serving patients in nearly 75 countries. For more details, visit www.jazzpharmaceuticals.com.
Jazz Pharmaceuticals (NASDAQ: JAZZ) is set to showcase its neuroscience advancements at the 75th Annual American Academy of Neurology Meeting, taking place from April 22-27, 2023 in Boston. The company will present eleven abstracts, including three oral presentations focused on idiopathic hypersomnia and essential tremor. Key findings include results from studies on Xywav, a low-sodium oxybate solution for treating narcolepsy and idiopathic hypersomnia, which showed significant efficacy in improving sleepiness. Additionally, retrospective analyses found that over 525,000 adults in the U.S. are diagnosed with essential tremor, highlighting the need for new treatment options. The event reinforces Jazz's commitment to addressing crucial neurological disorders.
The global cannabis pharmaceuticals market is projected to reach USD 127.1 billion by 2028, expanding at a CAGR of 104.2% from 2022. The COVID-19 pandemic has increased cannabis product consumption, notably in treating chronic illnesses like cancer and Parkinson's disease. Legalization in various countries bolsters market growth, with many regions recognizing medical cannabis as essential. Major players include Tilray (NASDAQ: TLRY) and Jazz Pharmaceuticals (NASDAQ: JAZZ), with significant partnerships, such as Brains Bioceutical's agreement with Prati-Donaduzzi for CBD supply in Brazil. Trulieve and Curaleaf are also expanding their market presence. Despite challenges, the cannabis pharmaceuticals sector is set for considerable expansion, driven by increasing demand and supportive legislation.
On March 30, 2023, Jazz Pharmaceuticals (Nasdaq: JAZZ) announced an initiative to enhance understanding of cardiovascular risks linked to sleep disorders in partnership with the American Heart Association. The collaboration aims to support educational resources for patients and healthcare providers, emphasizing the increased cardiovascular risks faced by individuals with sleep disorders like narcolepsy. With an estimated 50 to 70 million American adults affected, the campaign includes a dedicated website, a science advisory panel, and video series. This initiative is part of Jazz's commitment to pioneering treatments for sleep disorders and improving patient outcomes.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. Key data will focus on Zepzelca® (lurbinectedin), zanidatamab, and JZP898. Executive VP Rob Iannone highlighted the commitment to advancing oncology care with new immuno-oncology and targeted therapy candidates. Presentations will include findings on SLFN11 expression's predictive role in lurbinectedin's efficacy in small cell lung cancer and the anti-tumor activity of lurbinectedin in combination therapies. The full list of presentations is available on the AACR website.
Jazz Pharmaceuticals reported record revenues of $3.7 billion in 2022, an 18% increase from 2021, primarily driven by strong performance from its key products, Xywav and Epidiolex. The company generated $1.3 billion in cash from operations and successfully reduced its net debt leverage ratio to 2.9x. For 2023, Jazz forecasts total revenues between $3.675 billion and $3.875 billion, reflecting continued growth in its neuroscience and oncology portfolios. Xywav has become the largest product by net sales, annualizing over $1 billion, and the company plans to invest significantly in R&D to support its pipeline of new treatments.
On February 27, 2023, Jazz Pharmaceuticals (Nasdaq: JAZZ) announced its participation in two upcoming investor conferences. The first is the Cowen 43rd Annual Health Care Conference on March 7, 2023, in Boston, where management will participate in a fireside chat at 12:50 p.m. ET. The second is the J.P. Morgan 12th Annual Napa Valley Biotech Forum on March 21, 2023, in San Francisco, with a fireside chat at 1:45 p.m. ET. A live audio webcast of these events will be available on the Jazz Pharmaceuticals website, along with a replay for 30 days post-event.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) will release its financial results for the fourth quarter and full year 2022 on March 1, 2023, following the close of U.S. markets. A live audio webcast is scheduled for 4:30 p.m. ET / 9:30 p.m. GMT to discuss the financial outcomes and provide a business update. Interested individuals can register in advance through the company's website. Following the event, a replay will be available on Jazz's investor section. The company focuses on developing transformative medicines in neuroscience and oncology, with a commitment to addressing unmet medical needs globally.
Jazz Pharmaceuticals and Zymeworks announced results from a Phase 2 trial for zanidatamab, a HER2-targeted bispecific antibody, showcasing compelling efficacy in advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) patients. The trial revealed an overall confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 92%. Notably, the 18-month overall survival (OS) rate was 84%, with median progression-free survival (mPFS) of 12.5 months. The ongoing Phase 3 trial, HERIZON-GEA-01, is expected to provide further data that could support regulatory submissions.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) will webcast its corporate presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:45 p.m. PST / 11:45 p.m. GMT. CEO Bruce Cozadd will discuss the company's business and financial updates. Investors can access the live audio via Jazz Pharmaceuticals' website, with a replay available for 30 days post-conference. The company is committed to developing innovative medicines for patients with serious diseases across neuroscience and oncology, serving nearly 75 countries globally.
FAQ
What is the current stock price of Jazz Pharmaceuticals (JAZZ)?
What is the market cap of Jazz Pharmaceuticals (JAZZ)?
What does Jazz Pharmaceuticals specialize in?
What are some key products of Jazz Pharmaceuticals?
Where is Jazz Pharmaceuticals headquartered?
What recent achievements has Jazz Pharmaceuticals made?
What is zanidatamab?
How financially stable is Jazz Pharmaceuticals?
What partnerships does Jazz Pharmaceuticals have?
What is Jazz Pharmaceuticals' approach to business culture?
What are the company's future plans?
How can investors stay informed about Jazz Pharmaceuticals?
